Rani Therapeutics (RANI) vs Unicycive Therapeutics (UNCY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Rani Therapeutics (RANI) has outperformed Unicycive Therapeutics (UNCY) over the past year, gaining 61.6% versus a loss of 14.7%. Over five years, UNCY leads with a -85.1% price change compared with -96.0% for RANI. Unicycive Therapeutics is the larger company by market cap ($112.6 million vs $112.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | RANI | UNCY |
|---|---|---|
| Share price | $0.799 | $4.11 |
| Market cap | $112.28M | $112.59M |
| 1-day change | +0.88% | +0.98% |
| YTD return | -41.33% | -29.46% |
| 1-year return | +61.63% | -14.68% |
| 5-year return | -95.98% | -85.06% |
| Forward P/E | — | 2.44 |
| EPS (TTM) | $-0.15 | $-1.72 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.87 | $8.74 |
| 52-week low | $0.445 | $3.93 |
| Distance from 52-week high | -79.35% | -52.97% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +801.13% | +591.00% |
| Average volume | 743.68K | 839.29K |
| Shares outstanding | 115.42M | 27.39M |
| Employees | 69 | 21 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RANI has outperformed UNCY by 76.3 percentage points over the past year.
About Rani Therapeutics
RANI stock →Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 69 employees
About Unicycive Therapeutics
UNCY stock →Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator, which is in Phase I clinical trial for the treatment of acute kidney injury and pre-clinical stage for the treatment of chronic kidney disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
RANI vs UNCY FAQ
Which is bigger, Rani Therapeutics or Unicycive Therapeutics?
Unicycive Therapeutics (UNCY) is larger, with a market capitalization of $112.59M compared with $112.28M for Rani Therapeutics (RANI).
Which stock has performed better over the past year, RANI or UNCY?
RANI returned +61.63% over the past 12 months, compared with -14.68% for UNCY (price return, excluding dividends). Past performance does not predict future results.
Are Rani Therapeutics and Unicycive Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.